Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CGEN with free AI briefings, catalyst countdowns, and dilution alerts.

CGEN · COMPUGEN LTD

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$117.5M Cash on Hand
CF+ Cash Runway
Follow CGEN by email Get an email when CGEN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CGEN, unsubscribe in one click. Privacy

📣 What CGEN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Anti-PVRIG Monoclonal Antibody COM701 Ovarian Cancer Phase 1/2 · NCT06888921 Active not recruiting
Renvistobart Endometrial Neoplasms Phase 1/2 · NCT04570839 Completed
Cohort expansion: COM902 (RDFE) monotherapy. Advanced Cancer Phase 1 · NCT04354246 Completed
Anti-IL-18BP Monoclonal Antibody GS-0321 Neoplasm Phase 1 · NCT06759649 Recruiting
Dose escalation: COM902 monotherapy. Advanced Cancer Phase 1 · NCT04354246 Completed
Zimberelimab Neoplasm Phase 1 · NCT06759649 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CGEN holds $117.5M in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CGEN files for a raise →

👥 Who Owns CGEN

Insiders 0.4% Institutions (91 holders) 15.1% Public and other holders 84.5%
HolderTypeShares% of sharesAs of
Anat Cohen-Dayag
Director · +100,000 options
Insider 108,622 0.11% 2026-03-18
David Silberman
Chief Financial Officer · +26,000 options
Insider 55,000 0.06% 2026-07-29
Zurit Levine
SVP, Business Development · +79,750 options
Insider 47,375 0.05% 2026-07-29
Russo Sharon Kredo
SVP, Research & Discovery · +24,000 options
Insider 37,500 0.04% 2026-07-29
Michelle Mahler
Chief Medical Officer · +18,000 options
Insider 36,625 0.04% 2026-07-29
Savitzky Kinneret Livnat
Director · +10,000 options
Insider 20,850 0.02% 2026-07-29
Sanford S Zweifach
Director · +10,000 options
Insider 20,180 0.02% 2026-07-29
Gilead Halevy
Director · +10,000 options
Insider 18,907 0.02% 2026-07-29
Eran Perry
Director · +10,000 options
Insider 17,500 0.02% 2026-07-29
Mathias Hukkelhoven
Director · +10,000 options
Insider 17,500 0.02% 2026-07-29
Michele Holcomb
Director
Insider 15,000 0.02% 2026-03-18
Eran Ophir
President and CEO, Director · +214,375 options
Insider 11,375 0.01% 2026-04-24

Share count 94,553,191 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CGEN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CGEN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.